Objective: 1. To determine whether
naltrexone-accelerated detoxification with minimal sedation is an
acceptable and effective form of induction onto naltrexone. 2. To
monitor outcomes of detoxified patients.
Design: Observational study.
Setting: Medical ward of a general hospital (for
detoxification) and a community clinic (for follow-up) in Sydney,
NSW, 1998.
Patients: 15 heroin users and 15 people seeking
withdrawal from methadone.
Intervention: Detoxification used naltrexone (12.5 or
50 mg), with flunitrazepam (2-3 mg), clonidine (150-750 µg)
and octreotide (300 µg) for symptomatic support.
Patients remained awake and were discharged when they felt well
enough. Follow-up was daily for four days and then weekly for up to
three months for supportive care.
Main outcome measures: Acute side effects; patient
ratings of severity and acceptability of withdrawal; nights of
hospitalisation; rates of induction onto naltrexone; retention in
treatment over three months; and relapse to opioid use.
Results: Acute withdrawal with delirium lasted about
four hours. Octreotide was crucial for controlling vomiting; with
octreotide no patient required intravenous fluids. There were no
major complications. Eighteen patients (60%) reported that it was a
"quite" acceptable procedure, 18 (60%) required only one night's
hospitalisation, and 24 (80%) were successfully inducted onto
naltrexone (defined as taking naltrexone on Day 8). Three months
later, six (20%) were still taking naltrexone (with four of these
occasionally using heroin) and seven (23%) were abstinent from
opioids, including five not taking naltrexone. Eleven had gone onto
methadone maintenance, seven had relapsed to heroin use, and one had
died of a heroin overdose.
Conclusions: Rates of induction onto naltrexone were
comparable with those reported for accelerated detoxification
under sedation, suggesting that it can be performed successfully
with minimal sedation. As in other studies of naltrexone
maintenance, retention was low, and relapse to heroin use was
common.
- 1.
- Riordan CE, Kleber HD. Rapid opiate detoxification with clonidineand naltrexone. Lancet 1980; 5: 1079-1080.
- 2.
- O'Connor PG, Kosten TR. Rapid and ultrarapid opioiddetoxification techniques. JAMA 1998; 279: 229-234.
- 3.
- Kleber HD. Ultra-rapid opiate detoxification. Addiction1998; 92: 1929-1933.
- 4.
- Seoane A, Carrasco G, Cabre L, et al. Efficacy and safety of two newmethods of rapid intravenous detoxification in heroin addictspreviously treated without success. Br J Psych 1997; 171:340-345.
- 5.
- Handelsman L, Cochrane KJ, Aronson MJ, et al. Two new rating scalesfor opiate withdrawal. Am J Drug Alcohol Abuse 1987; 13:293-308.
- 6.
- Darke S, Hall W, Heather N, et al. Development and validation of amultidimensional instrument for assessing outcome of treatmentamong opioid users: the opiate treatment index. Br J Addict1992; 87: 593-602.
- 7.
- Mattick RP, Hall W. Are detoxification programmes effective?Lancet 1996; 347: 97-100.
- 8.
- Mayor S. Specialists criticise treatment for heroin addiction.BMJ 1997; 314: 1365.
- 9.
- Rabinowitz J, Cohen H, Tarrasch R, Kotler M. Compliance tonaltrexone after ultra-rapid opiate detoxification. DrugAlcohol Depend 1997; 47: 77-86.
- 10.
- Scherbaum N, Klein S, Kaube H, et al. Alternative strategies ofopiate detoxification: evaluation of the so-called ultra-rapiddetoxification. Pharmacopsychiatry 1998; 31: 205-209.
- 11.
- O'Connor PG, Carroll KM, Shi JM, et al. Three methods of opioiddetoxification in a primary care setting: a randomized trial. AnnIntern Med 1997; 127: 526-530.
- 12.
- Jaffe J. Pharmacological treatment of opioid dependence:Current techniques and new findings. Psychiatric Annals1995; 25: 369-375.
- 13.
- Tucker T, Ritter A. Naltrexone: a literature review. Melbourne:Turning Point Alcohol and Drug Centre, 1998.
- 14.
- Kleber HD. Naltrexone. J Substance Abuse Treatment 1985;2: 117-122.
- 15.
- Australian Medical Procedures Research Foundation. PerthNaltrexone Trial report. Perth: AMPRF, 1999.
- 16.
- Foy A, Sadler C, Taylor A. An open trial of naltrexone for opiatedependence. Drug Alcohol Rev 1998; 17: 167-174.
- 17.
- Miotto K, McCann MJ, Rawson RA, et al. Overdose, suicide attemptsand death among a cohort of naltrexone-treated opioid addicts.Drug Alcohol Depend 1997; 45: 131-134.